These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 7855782)
1. Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients. Azar AJ; Deckers JW; Rosendaal FR; van Bergen PF; van der Meer FJ; Jonker JJ; Briët E Thromb Haemost; 1994 Sep; 72(3):347-51. PubMed ID: 7855782 [TBL] [Abstract][Full Text] [Related]
2. Subtherapeutic oral anticoagulant therapy: frequency and risk factors. Rombouts EK; Rosendaal FR; van der Meer FJ Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419 [TBL] [Abstract][Full Text] [Related]
3. Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements. van Geest-Daalderop JH; Péquériaux NC; van den Besselaar AM Thromb Haemost; 2009 Sep; 102(3):588-92. PubMed ID: 19718481 [TBL] [Abstract][Full Text] [Related]
4. [Quality control of ISI/INR system in oral anticoagulant therapy]. Kazama M Rinsho Ketsueki; 1990 Jun; 31(6):769-75. PubMed ID: 2214167 [TBL] [Abstract][Full Text] [Related]
5. Optimal oral anticoagulant therapy in patients with mechanical heart valves. Cannegieter SC; Rosendaal FR; Wintzen AR; van der Meer FJ; Vandenbroucke JP; Briët E N Engl J Med; 1995 Jul; 333(1):11-7. PubMed ID: 7776988 [TBL] [Abstract][Full Text] [Related]
6. [A retrospective survey on practice of oral anticoagulant therapy in patients with cardiovascular diseases]. Katona A; Márk L Orv Hetil; 2004 Aug; 145(32):1643-7. PubMed ID: 15384862 [TBL] [Abstract][Full Text] [Related]
7. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Penning-van Beest FJ; van Meegen E; Rosendaal FR; Stricker BH Thromb Haemost; 2001 Aug; 86(2):569-74. PubMed ID: 11522005 [TBL] [Abstract][Full Text] [Related]
8. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK). Cosmi B; Palareti G; Carpanedo M; Pengo V; Biasiolo A; Rampazzo P; Morstabilini G; Testa S Haematologica; 2000 Aug; 85(8):826-31. PubMed ID: 10942929 [TBL] [Abstract][Full Text] [Related]
9. Understanding low INR in clinical practice. Hylek EM; Rose AJ Thromb Haemost; 2009 Mar; 101(3):417-8. PubMed ID: 19277399 [No Abstract] [Full Text] [Related]
10. [Is optimal anticoagulation possible in ambulatory practice? Report on a retrospective 5-year study of a cardiology practice]. von Bertrab R Schweiz Med Wochenschr; 1985 Aug; 115(31-32):1092-105. PubMed ID: 4048907 [TBL] [Abstract][Full Text] [Related]
11. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon. van Leeuwen Y; Rosendaal FR; van der Meer FJ Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321 [TBL] [Abstract][Full Text] [Related]
12. [Extent and quality of anti-coagulation treatment with coumarin derivatives by the Dutch Thrombosis Services]. van Geest-Daalderop JH; Sturk A; Levi M; Adriaansen HJ Ned Tijdschr Geneeskd; 2004 Apr; 148(15):730-5. PubMed ID: 15119208 [TBL] [Abstract][Full Text] [Related]
13. Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction. Azar AJ; Koudstaal PJ; Wintzen AR; van Bergen PF; Jonker JJ; Deckers JW Ann Neurol; 1996 Mar; 39(3):301-7. PubMed ID: 8602748 [TBL] [Abstract][Full Text] [Related]
14. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163 [TBL] [Abstract][Full Text] [Related]
15. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet; 1994 Feb; 343(8896):499-503. PubMed ID: 7906757 [TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Rossini R; Musumeci G; Lettieri C; Molfese M; Mihalcsik L; Mantovani P; Sirbu V; Bass TA; Della Rovere F; Gavazzi A; Angiolillo DJ Am J Cardiol; 2008 Dec; 102(12):1618-23. PubMed ID: 19064015 [TBL] [Abstract][Full Text] [Related]
17. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Maitland-van der Zee AH; ; Thromb Res; 2015 Jul; 136(1):94-100. PubMed ID: 25971661 [TBL] [Abstract][Full Text] [Related]
18. Anticoagulant therapy after prosthetic valve replacement -optimal PT-INR in Japanese patients-. Mori T; Asano M; Ohtake H; Bitoh A; Sekiguchi S; Matsuo Y; Aiba M; Yamada M; Kawada T; Takaba T Ann Thorac Cardiovasc Surg; 2002 Apr; 8(2):83-7. PubMed ID: 12027793 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Gadisseur AP; Breukink-Engbers WG; van der Meer FJ; van den Besselaar AM; Sturk A; Rosendaal FR Arch Intern Med; 2003 Nov; 163(21):2639-46. PubMed ID: 14638565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]